Pegylated interferon for the treatment of high-risk essential thrombocythemia

Haematologica. 2005 Oct;90(10):1298B.

Author

Ruben Mesa¹

Affiliation

¹ Division of Hematology and Internal Medicine, Division of Hematopathology, Cancer Center Statistics Unit, Mayo Clinic, Rochester, USA. mesa.ruben@mayo.edu

PMID: 16219553

No abstract available

Publication types

Comment

MeSH terms

Clinical Trials, Phase II as Topic
Humans
Interferon alpha-2
Interferon-alpha / therapeutic use*
Platelet Count
Recombinant Proteins
Risk Factors
Thrombocythemia, Essential / blood
Thrombocythemia, Essential / drug therapy*
Thrombocythemia, Essential / epidemiology

Substances

Interferon alpha-2
Interferon-alpha
Recombinant Proteins